Of Il 1 b , Il 4 , Il 5 And Ige Before And After Mirazid Therapy In Children With Intestinal

This study was planned to evaluate the effectiveness of Myrrh in children with hepatic fascioliasis and intestinal schistosomiasis through study of clinical and parasitologic cures and assessment of serum total IgE and production of IL-1, IL-4 and IL-5 by peripheral blood mononuclear cells (PBMCs) before and after Mirazid therapy. The study included 21 children with fascioliasis, 8 children with Schistosoma mansoni infection in addition to 10 healthy children with matched age and sex as control. Diagnosis was based on the detection of Fasciola hepatica or Schistosoma Mansoni eggs in stool analysis. Patients were given the recommended dose of Mirazid. Clinical evaluation and stool analysis were done initially and at 2, 4, 12 weeks post treatment to evaluate cure. Rectal snip was done for responding schistosomiasis cases to confirm recovery. Total IgE was measured in serum by enzyme immunoassay. PBMNCs were separated and cultured for 48 hours and cytokines production in response to PHA stimulation was assessed in culture supernatants by solid phase sandwich enzyme-linked immunosorbent assay. Parasitologic cure was 90.9% in the fasciola group and 100% in the schistosoma group at 4weeks post treatment. After a second dose the fasciola patients who remained positive were also cured. Total IgE was significantly higher in both fasciola and schistosoma groups before treatment compared with control and decreased significantly with. IL-1 was higher in both patient groups than control and it did decrease significantly 12 weeks after therapy. Similarly, IL-5 was high before treatment in both groups and decreased significantly after 12 weeks of treatment. IL4 on the other hand did not differ from control before therapy but it increased significantly after treatment in both fasciola and schistosoma group. Therefore, Mirazid is an effective fasciolicidal and schistosomicidal drug. IL-1 and IL-5 are high in fasciola and schistosoma infection and decrease with therapy that may denote a role in immunopathogenesis. Cytokines level but not total IgE may be taken as criteria of cure. [Adul-Samiea ER, Soliman OS, El-Nemr H, Masoud A: A Study of Immune Status with Mirazid Therapy. New York Science Journal 2010;3(12):116-122]. (ISSN: 1554-0200). http://www.sciencepub.net/newyork.